Novo Nordisk's 7.2mg semaglutide marketing application accepted by EMA

According to the Wise Finance APP, on July 8th, Novo Nordisk (NVO.US) announced that the marketing application for 7.2mg semaglutide has been accepted by the European Medicines Agency (EMA) for weight management. This marketing application is based on the positive results of the Phase III STEP UP study and the Phase III STEP UP T2D study.